BioSpace News Archive

Oryzon Genomics, S.A. reported financial results for the fourth quarter ended December 31, 2022 and provided an update on recent developments.

The board of directors of Abbott declared a quarterly common dividend of 51 cents per share.

Paragon 28, Inc. announced completion of the sale of an additional 975,000 shares of its common stock, pursuant to the exercise in full of the option to purchase additional shares granted to the underwriters in connection with Paragon’s recently completed underwritten public offering of 6,500,000 shares of common stock, at a public offering price of $17.00 per share, before underwriting discounts and commissions.

Bristol Myers Squibb announced three-year follow-up results from the Phase 3 CheckMate -274 trial, demonstrating significant sustained clinical benefits with Opdivo for the adjuvant treatment of patients with surgically resected, high-risk muscle-invasive urothelial carcinoma.

Sutro Biopharma, Inc. announced that on February 15, 2023, the Compensation Committee of Sutro’s Board of Directors granted 90,000 shares of Sutro Biopharma stock options and 130,000 restricted stock units of Sutro common stock.

Travere Therapeutics, Inc. announced that the U.S. Food and Drug Administration has granted accelerated approval to FILSPARI™ to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio ≥1.5 g/g.

TransCode Therapeutics, Inc. announced the closing of its previously announced registered direct offering of 2,846,300 shares of common stock priced at-the-market under Nasdaq rules at $0.527 per share for gross proceeds of $1.5 million.

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company and leader in complement, announced that the U.S. Food and Drug Administration has approved SYFOVRE™ for the treatment of geographic atrophy secondary to age-related macular degeneration.

LumiraDx Limited announced that it has received confirmation from The Nasdaq Stock Market LLC that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450.

Ligand Pharmaceuticals Incorporated announced that its partner Travere Therapeutics, Inc. has received accelerated approval from the U.S. Food and Drug Administration for FILSPARI™ to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio ≥1.5 g/g.